Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs)
Official title: ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
9000
Start Date
2021-09-02
Completion Date
2033-07-26
Last Updated
2025-06-26
Healthy Volunteers
No
Conditions
Locations (1)
Evidera
Bethesda, Maryland, United States